Solventum opened higher at $84.15, compared with its previous close of $83.56. In the last trading session, the stock traded between $81.33 and $84.48. It showed a downward intraday trend.
return calculator
Time Period
An investment of $100 made 3 years ago in Solventum is now worth
$ 118.01
giving a profit of
$ 18.01 (18.01%)
invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 10 Analysts
Buy
70%
Hold
30%
Sell
0%
Markets Today
Today's Change
$-2.02 (-2.41%)
Day High
$84.48
Day Low
$81.33
Day Open
$84.15
Prev Close
$83.56
Volume
2,34,967
1W Return
-6.76%
1M Return
-8.74%
3M Return
-7.87%
6M Return
22.64%
1Y Return
16.86%
Fundamentals
Market Cap ($ Mn)
13,881
PE Ratio
11.15
PB Ratio
3.23
PEG Ratio
1.82
ROE
39.09%
ROCE
17.65%
EPS (TTM)
-
Investment Returns
1 Week
-6.76%
1 Month
-8.74%
3 Months
-7.87%
6 Months
22.64%
9 Months
6.57%
Financials
Quarterly
All values in $ Mn
2.1K
Mar 25
2.2K
Jun 25
2.1K
Sep 25
2.0K
Dec 25
2.0K
Mar 26
2.2K
Jun 26
Updates
20Oct
Solventum secures FDA clearance for combined wound healing therapy
FDA grants 510(k) clearance for combined use of Restrata Matrix and V.A.C. Therapy. Clearance follows Solventum's December 2025 acquisition of Acera Surgical. Integration creates a unified path for active wound healing support.
10 days ago
6Aug
BTIG raises Solventum price target to $95 on Buy rating
BTIG analyst Ryan Zimmerman maintains a Buy rating on Solventum (NYSE: SOLV) and raises the price target from $91 to $95. The move indicates strong analyst confidence in the stock's value proposition.
2mo ago
6Aug
Solventum plans separation of Health Information Systems business
Solventum plans to separate its Health Information Systems business to optimize its portfolio. The company will evaluate various separation pathways to maximize shareholder value and ensure long-term success for both entities. No specific timeline or financial details were provided.
2mo ago
16Jul
Solventum to report Q2 FY26 earnings on August 5, 2026
Solventum will announce its Q2 FY26 financial results on August 5, 2026, post-market close. A webcast will follow to discuss the results and other material information.
3mo ago
9Jul
BMO Capital initiates Solventum coverage with $81 price target
BMO Capital has initiated coverage on Solventum with a Market Perform rating and a price target of $81, indicating a neutral market outlook.
